

00637962-081100




Figure 1

00637952-081100




Figure 2

09637962.081.100

Molecular weight
standards
(Lane 1)

STD	Ω	HSA	Ω	$\Omega\alpha$	β	Ω	α	β	Ω	Ω	
1	2	3	4	5	6	7	8	9	10	11	12
↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓

97 kD →
66 kD →
45 kD →
31 kD →
22 kD →
14 kD →



Figure 3

00180 2354E950




Figure 4




Figure 5




Figure 6

09637962-03100

Figure 6 C





Figure 6 D



PLATELETS

teen patients treated for 16 weeks

g/week)

Patient	Platelet Count (g/week)
1	~420
2	~480
3	~450
4	~480
5	~480
6	~480
7	~480
8	~480
9	~480
10	~480
11	~480
12	~480
13	~480
14	~480
15	~480
16	~480

PLATELETS

teen patients treated for 16 weeks

g/week)

Patient	Platelet Count (g/week)
1	~420
2	~480
3	~450
4	~480
5	~480
6	~480
7	~480
8	~480
9	~480
10	~480
11	~480
12	~480
13	~480
14	~480
15	~480
16	~480



PLT. AVE. — DOSE

DOVER




Figure 8

Figure 9A




Figure 9B

Comparison of epoetin alfa and epoetin beta




Fig. 2. Actual serum epoetin concentrations (mean \pm SD) before and after subcutaneous administration (100 U/kg) of epoetin beta (O), epoetin (●), and placebo (Δ). * $p < 0.05$, epoetin beta versus epoetin alfa.

09637962 081100

00180-2967E960

Plasma epo (IU/L)





Figure 9

A



B




Figure 10




Figure 11

00637962-081100




Figure 12




Figure 13




Figure 14







Figure 15

001180-2967E960

Figure 15

C



00637962-001100




Figure 16







Figure 17

Figure 18 A



DOSES

HEMOGLOBIN

BP

Figure 18 B






Figure 18 C











Figure 19




001100 2967962 2967962

Figure 20


A



B




C



001F80"2964E960

Figure 21

A



B





Figure 22

Treatment During Chemotherapy
Weekly Dosing Epoetin Omega v. Epoetin Alpha



■ Epoetin Omega Low Dose Per Week ■ Epoetin Omega High Dose Per Week
▨ Epoetin Alpha Low Dose Per Week ▨ Epoetin Alpha High Dose Per Week

Figure 23

Treatment During Chemotherapy
Starting v. Ending Hemoglobin 8 weeks




Figure 24

Dose Comparison in Treating Anemia of Prematurity






Figure 25



09637962-081100

Figure 26.



09637962-081100